Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin
Introduction Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead. Case presentation The patient pres...
Saved in:
| Published in | IJU case reports Vol. 7; no. 6; pp. 434 - 437 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Tokyo
John Wiley & Sons, Inc
01.11.2024
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Introduction
Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead.
Case presentation
The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2‐3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m2 on days 1 and 2), paclitaxel (120 mg/m2 on day 1), and 5‐fluorouracil (1000 mg/m2 on days 2–5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well.
Conclusion
A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported. |
|---|---|
| AbstractList | Introduction Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead. Case presentation The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2‐3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m2 on days 1 and 2), paclitaxel (120 mg/m2 on day 1), and 5‐fluorouracil (1000 mg/m2 on days 2–5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well. Conclusion A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported. Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead.IntroductionCisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead.The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2-3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m2 on days 1 and 2), paclitaxel (120 mg/m2 on day 1), and 5-fluorouracil (1000 mg/m2 on days 2-5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well.Case presentationThe patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2-3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m2 on days 1 and 2), paclitaxel (120 mg/m2 on day 1), and 5-fluorouracil (1000 mg/m2 on days 2-5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well.A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported.ConclusionA case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported. Introduction Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead. Case presentation The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2‐3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m2 on days 1 and 2), paclitaxel (120 mg/m2 on day 1), and 5‐fluorouracil (1000 mg/m2 on days 2–5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well. Conclusion A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported. Introduction Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who cannot tolerate cisplatin. This report describes a case in which carboplatin was used instead. Case presentation The patient presented with a chief complaint of edema in the groin area. On close examination, penile cancer (cT2‐3N3M0 stage IV) with pelvic lymph node metastasis was diagnosed. He was started on chemotherapy with cisplatin (50 mg/m 2 on days 1 and 2), paclitaxel (120 mg/m 2 on day 1), and 5‐fluorouracil (1000 mg/m 2 on days 2–5), but he developed acute kidney failure on the 12th day, thought to be caused by cisplatin. Cisplatin was changed to carboplatin, and chemotherapy was continued. He has received nine courses of chemotherapy and is doing well. Conclusion A case of penile cancer safely and effectively treated with chemotherapy using carboplatin was reported. |
| Author | Wakai, Ken Naya, Yukio Sekine, Keita Okato, Atsushi Suyama, Takahito Takei, Kazuki Kato, Hiroto Yamazaki, Kazuto Hou, Kyokushin Araki, Kazuhiro |
| AuthorAffiliation | 4 Present address: Chosei Municipal Hospital Chiba Japan 1 Department of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan 6 Present address: QST Hospital Chiba Japan 5 Present address: Teikyo University Tokyo Japan 3 Present address: Chibaken Saiseikai Narashino Hospital Chiba Japan 2 Department of Pathology Teikyo University Chiba Medical Center Ichihara Chiba Japan |
| AuthorAffiliation_xml | – name: 1 Department of Urology Teikyo University Chiba Medical Center Ichihara Chiba Japan – name: 4 Present address: Chosei Municipal Hospital Chiba Japan – name: 5 Present address: Teikyo University Tokyo Japan – name: 6 Present address: QST Hospital Chiba Japan – name: 3 Present address: Chibaken Saiseikai Narashino Hospital Chiba Japan – name: 2 Department of Pathology Teikyo University Chiba Medical Center Ichihara Chiba Japan |
| Author_xml | – sequence: 1 givenname: Keita surname: Sekine fullname: Sekine, Keita organization: Teikyo University Chiba Medical Center – sequence: 2 givenname: Takahito orcidid: 0000-0002-9487-1397 surname: Suyama fullname: Suyama, Takahito email: takahitosuyama@yahoo.co.jp organization: Teikyo University Chiba Medical Center – sequence: 3 givenname: Kazuki surname: Takei fullname: Takei, Kazuki organization: Teikyo University Chiba Medical Center – sequence: 4 givenname: Hiroto surname: Kato fullname: Kato, Hiroto organization: Teikyo University Chiba Medical Center – sequence: 5 givenname: Ken surname: Wakai fullname: Wakai, Ken organization: Teikyo University Chiba Medical Center – sequence: 6 givenname: Atsushi surname: Okato fullname: Okato, Atsushi organization: Teikyo University Chiba Medical Center – sequence: 7 givenname: Kyokushin surname: Hou fullname: Hou, Kyokushin organization: Teikyo University Chiba Medical Center – sequence: 8 givenname: Kazuhiro surname: Araki fullname: Araki, Kazuhiro organization: Teikyo University Chiba Medical Center – sequence: 9 givenname: Kazuto surname: Yamazaki fullname: Yamazaki, Kazuto organization: Teikyo University Chiba Medical Center – sequence: 10 givenname: Yukio orcidid: 0000-0002-2008-6951 surname: Naya fullname: Naya, Yukio organization: Teikyo University Chiba Medical Center |
| BookMark | eNp9klFrHCEQx5eSQNMkL_0EC30phUtHXVfzVEpomwuBPiSBvonrzt557OpW3YT79nWz19L0oSg44_zmr6Pzpjhy3mFRvCVwQQDoR7ub-AWhQtBXxQnlQqyIID-O_rJfF-cx7iDDQFhd0ZMi3T3ZZLbWbUpj49jrZF2ZfGl0aPzBzdNscfBpi0GP-7LzoRww6Zhy2JQjOttjznAGwwzrcswBdCk7yfc5KZuz5u8DzorjTvcRzw_rafHw9cv91fXq9vu39dXn25VhktCVbChgRS4NGE4AtTCSM9qxmuuKsU6wqjEdsA5Rtogg8yAgjNCXHUjdITst1otu6_VOjcEOOuyV11Y9b_iwUTrkEnpUwGpdZV1ZybZqeS1bQAO81qIBII3OWp8WrXFqBmxNLi_o_oXoy4izW7Xxj4oQzoiUIiu8PygE_3PCmNRgo8G-1w79FBUjtCK0BkEz-u4fdOen4PJbzRTjkoMkmfqwUCb4GAN2f25DQM0doeaOUM8dkWGywE_5s_b_IdX65oEvOb8AUS-7-Q |
| Cites_doi | 10.1016/S0022-5347(01)62402-9 10.1038/bjc.2013.620 10.1016/S0022-5347(17)49693-5 10.1016/S0022-5347(17)32520-X 10.1016/j.euf.2022.02.007 10.18632/oncotarget.4802 10.1016/j.eururo.2008.07.014 10.3109/02841868809094366 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 The Author(s). IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. |
| Copyright_xml | – notice: 2024 The Author(s). published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. – notice: 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 The Author(s). IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. |
| DBID | 24P WIN AAYXX CITATION 3V. 7RV 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1002/iju5.12772 |
| DatabaseName | Wiley_OA刊 Wiley-Blackwell Backfiles (Open access) CrossRef ProQuest Central (Corporate) Proquest Nursing & Allied Health Source Health & Medical Complete (ProQuest Database) ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Nursing & Allied Health Premium ProQuest - Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley_OA刊 url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Carboplatin for cisplatin unfit penile cancer |
| EISSN | 2577-171X |
| EndPage | 437 |
| ExternalDocumentID | oai_doaj_org_article_036a45a4848d4d568d0ec056a7b001ba 10_1002_iju5_12772 IJU512772 |
| Genre | caseStudy Report Case Study |
| GroupedDBID | 0R~ 1OC 24P 7RV 7X7 8FI 8FJ AAHHS ABUWG ACCFJ ACXQS ADBBV ADKYN ADPDF ADZMN ADZOD AEEZP AEQDE AFKRA AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS AVUZU BCNDV BENPR CCPQU EBS EJD FYUFA GROUPED_DOAJ HMCUK IAO IHR INH ITC M~E NAPCQ OK1 OVD OVEED PIMPY PQQKQ RPM TEORI UKHRP WIN AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c3812-8b20e419c0c510ea7c8532f365a433f734bcf03fee8dee08080107c7a9f08afe3 |
| IEDL.DBID | RPM |
| ISSN | 2577-171X |
| IngestDate | Mon Nov 04 19:59:50 EST 2024 Tue Nov 05 05:28:02 EST 2024 Wed Nov 06 16:47:50 EST 2024 Mon Nov 04 02:24:48 EST 2024 Wed Nov 06 13:18:41 EST 2024 Mon Nov 04 11:01:36 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3812-8b20e419c0c510ea7c8532f365a433f734bcf03fee8dee08080107c7a9f08afe3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-9487-1397 0000-0002-2008-6951 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531887/ |
| PQID | 3123585081 |
| PQPubID | 4570189 |
| PageCount | 4 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_036a45a4848d4d568d0ec056a7b001ba pubmedcentral_primary_oai_pubmedcentral_nih_gov_11531887 proquest_miscellaneous_3124126072 proquest_journals_3123585081 crossref_primary_10_1002_iju5_12772 wiley_primary_10_1002_iju5_12772_IJU512772 |
| PublicationCentury | 2000 |
| PublicationDate | November 2024 |
| PublicationDateYYYYMMDD | 2024-11-01 |
| PublicationDate_xml | – month: 11 year: 2024 text: November 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Tokyo |
| PublicationPlace_xml | – name: Tokyo – name: Hoboken |
| PublicationTitle | IJU case reports |
| PublicationYear | 2024 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2009; 55 2007 1998; 160 1984; 132 2015; 6 2013; 109 1990; 143 1994; 152 2022; 8 1988; 27 e_1_2_12_4_1 e_1_2_12_3_1 e_1_2_12_5_1 Pettaway CA (e_1_2_12_2_1) 2007 Fisher HA (e_1_2_12_6_1) 1990; 143 e_1_2_12_14_1 e_1_2_12_13_1 e_1_2_12_12_1 e_1_2_12_8_1 e_1_2_12_11_1 e_1_2_12_7_1 e_1_2_12_10_1 e_1_2_12_9_1 |
| References_xml | – volume: 27 start-page: 823 year: 1988 end-page: 824 article-title: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis publication-title: Acta Oncol. – volume: 152 start-page: 1124 year: 1994 end-page: 1126 article-title: Neoadjuvant cisplatin and interferon‐alpha 2B in the treatment and organ preservation of penile carcinoma publication-title: J. Urol. – volume: 8 start-page: 1687 year: 2022 end-page: 1695 article-title: Reassessment of the efficacy of carboplatin for metastatic urothelial carcinoma in the era of immunotherapy: a systematic review and meta‐analysis publication-title: Eur. Urol. Focus – volume: 160 start-page: 1770 year: 1998 end-page: 1774 article-title: Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase I study of methotrexate, cisplatin, and bleomycin publication-title: J. Urol. – start-page: 959 year: 2007 end-page: 992 – volume: 55 start-page: 546 year: 2009 end-page: 551 article-title: Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results publication-title: Eur. Urol. – volume: 143 start-page: 352A year: 1990 article-title: Neoadjuvant therapy with cisplatin and 5‐fluorouracil for stage III squamous cell carcinoma of the penis publication-title: J. Urol. – volume: 109 start-page: 2554 year: 2013 end-page: 2559 article-title: Phase II trial of docetaxel, cisplatin, and 5FU chemotherapy in locally advanced and metastatic penis cancer. (CRUK/09/001) publication-title: Br. J. Cancer – volume: 6 start-page: 32212 year: 2015 end-page: 32219 article-title: Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first‐line chemotherapy publication-title: Oncotarget. – volume: 132 start-page: 465 year: 1984 end-page: 468 article-title: Sequential trials of methotrexate, cisplatin, and bleomycin for penile cancer publication-title: J. Urol. – ident: e_1_2_12_13_1 – ident: e_1_2_12_7_1 doi: 10.1016/S0022-5347(01)62402-9 – start-page: 959 volume-title: Campbell‐Walsh Urology (ed 9) year: 2007 ident: e_1_2_12_2_1 contributor: fullname: Pettaway CA – volume: 143 start-page: 352A year: 1990 ident: e_1_2_12_6_1 article-title: Neoadjuvant therapy with cisplatin and 5‐fluorouracil for stage III squamous cell carcinoma of the penis publication-title: J. Urol. contributor: fullname: Fisher HA – ident: e_1_2_12_11_1 doi: 10.1038/bjc.2013.620 – ident: e_1_2_12_4_1 doi: 10.1016/S0022-5347(17)49693-5 – ident: e_1_2_12_8_1 doi: 10.1016/S0022-5347(17)32520-X – ident: e_1_2_12_12_1 doi: 10.1016/j.euf.2022.02.007 – ident: e_1_2_12_10_1 doi: 10.18632/oncotarget.4802 – ident: e_1_2_12_9_1 doi: 10.1016/j.eururo.2008.07.014 – ident: e_1_2_12_14_1 – ident: e_1_2_12_3_1 – ident: e_1_2_12_5_1 doi: 10.3109/02841868809094366 |
| SSID | ssj0002013642 |
| Score | 2.3195128 |
| Snippet | Introduction
Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for... Introduction Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for... Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for patients who... |
| SourceID | doaj pubmedcentral proquest crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Publisher |
| StartPage | 434 |
| SubjectTerms | advanced penile cancer Angina pectoris Cancer therapies carboplatin Case Report Chemotherapy cisplatin unfit Conflicts of interest Creatinine Edema Esophagus Genital cancers Human papillomavirus Kidney diseases Lymphatic system Metastasis Penis Squamous cell carcinoma Thrombocytopenia Tomography Tumors Urology |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqTlwqKkANBWRET5VSHD9i5wgIRJHopV2Jm-X4oQaVZLVkhfj3jJ3sasOhXCrl4MR2bM_Ynm9k-zNCX7n3RHjJcipdmXPqZG5qWeWidKXktpA2REfx7md5M-O39-J-46qvuCdsoAceBHcGM6zhwnDFleNOlMoRb8FqGxntfT1AI1JtOFMPaXmtYICs13yk9Kx5WIrvBZWSTixQIuqfoMu3eyM3MWsyOtc76OOIFvH5UMtP6INvd1H_67np0xZIbJunedzM1uK-w9Ys6m58hQe08Tger3rBAE3xo-9NPD_UWDz3LRQHOUDli5jY4JFgFV767i9kgmD856qAPTS7vvp9eZOPlyfkFowwzHI1JZ4XlSUWhp030oJhpoGVIEvGgmS8toGw4L1yoK9ILwmeoJWmCkSZ4Nk-2mq71n9GODgnwKtiwQL6KqyqvLKK1BFcCUNqlaHTlUD1fODI0AMbMtVR7DqJPUMXUdbrFJHXOn0AbetR2_o9bWfocKUpPQ62J83SeV9AmkWGTtbRMEzi2odpfbdMaXgBvlush5poeFKhaUzb_EmE24CaYepTMkPfUmf4Ryv1j9uZSKGD_9HeL2ibAooaDj8eoq1-sfRHgIL6-jh1-FcD7Acc priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbxQhFCe6vXgxmmocWw1NPZmMZfgY2JOxpk3bpI1RN-mNMHzoNO3Mujsb43_vg2VXp4cmc4ABBoYHvN_j4wdC77j3RHjJSipdXXLqZGkaOS1F7WrJbSVtiIbi5VV9NuMX1-I6T7gt87bKzZiYBmrX2zhHfsTSoU6AE9XH-a8y3hoVV1fzFRqP0Q4FS4FM0M7xydWXr9tZFhopyTjd8pLSo_ZmJT5UVEo60kSJsH-EMu_vkfwfuyblc_oMPc2oEX9ai_k5euS7XTR8-90OaSsktu1yHje1dXjosTWLps9eeEAqd_mY1R8MEBXf-cHEc0StxXPfQXaQAkS_iJENzkSr4Bn6W0gEzvjNTQYv0Oz05PvnszJfolBaUMYw2jWUeF5NLbHQ_byRFhQ0DawWhjMWJOONDYQF75UDuUWaSbAIrTTTQJQJnr1Ek67v_CuEg3MCrCsWLKCwyqqpV1aRJoIsYUijCnS4qVA9X3Nl6DUrMtWx2nWq9gIdx7rexoj81ulFv_ihc3fRoFcNhxIqrhx3olaOeAtYzciI8hpToP2NpHTudEv9r4kU6GAbDN0lroGYzverFIdXYMPFcqiRhEcFGod07c9EvA3oGYZAJQv0PjWGB_5Sn1_MRHK9frioe-gJBZy0Pt64jybDYuXfAM4Zmre5Mf8FnCEAVA priority: 102 providerName: ProQuest – databaseName: Wiley_OA刊 dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Ni9QwFA_revEiyipW16WiJ6Fum48mA15WcVkXFEEH5hbyqV3cdpjpIP73vpd2utaDsNBD2yRNmvde3i9t3i-EvOIhlCJIVlDp64JTLwtj5aIQta8ld5V0ESeKnz7XF0t-uRKrA_J2Hwsz8ENMH9zQMtJ4jQZu7Pb0hjS0udqJNxUFdHiH3EXKGGTOp_zL9IWFIh1Z2j0H1BKZEKvVxE9KT2-KzzxSIu6foc1_10r-jWGTEzp_QO6P6DE_G8T9kByE9oj0X381fVoSmbtmu8bFbW3ed7kzG9uNl3CAdK7HcKvfOUDV_Dr0BuOJGpevQwvVQQlQgQ1mNvlIuAoXffcTCsEpPnNfwSOyPP_w7f1FMW6mUDhwyjDqWVoGXi1c6cAMg5EOHDWNrBaGMxYl49bFksUQlAf5Id0kzAydNItYKhMDe0wO264NT0gevRcwy2LRARqrnFoE5VRpEWwJU1qVkZf7DtXrgTNDD-zIVGO369TtGXmHfT3lQJ7rdKPbfNej2Wjwr4ZDCxVXnntRK18GB5jNSER71mTkeC8pPRrfVrMU_wvIs8rIiykZzAb_hZg2dLuUh1cwl8N2qJmEZw2ap7TNj0TADdoGQ6GSGXmdlOE_b6k_Xi5FOnt6m8zPyD0K6GkIejwmh_1mF54D-untSVLyPyrJAdY priority: 102 providerName: Wiley-Blackwell |
| Title | Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fiju5.12772 https://www.proquest.com/docview/3123585081 https://www.proquest.com/docview/3124126072 https://pubmed.ncbi.nlm.nih.gov/PMC11531887 https://doaj.org/article/036a45a4848d4d568d0ec056a7b001ba |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-a7mUvY2Md89oFjfZp4MTWh6U8rqWlLbSEbYG8GUmWN5fGDqnD2H-_k2KHeg97GBgjWZIl606-31l3Z4Az7lwinGQxlUUWc1rIWBs5i0VWZJLbVNrSK4p399n1gt8uxfIAst4XJhjtW1NN6sfVpK5-BtvK9cpOezux6fzuAlEMsqKS0xGMkEOf6egPYWstZYiq97FI6bR62IpJSqWkA-kTgvQPkOXfdpHP8WoQOFev4VWHFMmX3YjewIGr30L77VfVBvNHYquntTdkq0nbEKs3pumyeCAlVp1r1W-CsJSsXKu971BlydrV2B22QHJvfGVNuuCqmGmbR2yESX_PvoMjWFxdfr-4jrsfJ8QWBTC-4QxNHE9nNrG45JyWFoUyLVkmNGeslIwbWyasdE4VSCsfWhK1QCv1rEyULh17B4d1U7v3QMqiEKhRsdIi8kqtmjllVWI8sBI6MSqC035C8_UuPka-i4RMcz_teZj2CM79XO9r-JjW4UKz-ZF3lM1RlmqOI1RcFbwQmSoSZxGfaemRndERnPSUyruF9pSz4OuLKDON4NO-GJeI3_fQtWu2oQ5PUW_z41ADCg8GNCxB3gvBtntei-BzYIZ_PGV-c7sQIfXh__s5hpcUcdPO3fEEDtvN1n1E3NOaMYwon-NZLuUYXpxf3s-_jsM3hHFYAH8A5yEK-g |
| link.rule.ids | 230,315,730,783,787,867,888,2109,11574,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,46064,46488,50826,50935,53804,53806,74079,74636 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLdgHOCChgAR2MAITkhhiWPH7mkCxNSNbRdWqTfL8QcEsaS0qRD__d5z3UI4TMrBju3Yec_2-_nrZ0Lecu8L4WWVM-nqnDMnc9PISS5qV0tuS2kDDhQvLuvpjJ_NxTxNuK3Stsptnxg7atdbnCM_quKhToAT5fHiV463RuHqarpC4y65hzxceIOBnMvdHAtDQjLOdqyk7Kj9sRbvSyYlG9mhSNc_wpj_75D8F7lG03OyTx4mzEg_bJT8iNzx3WMyfP3dDnEjJLXtaoFb2jo69NSaZdMnLzygk-t0yOoPBYBKr_1g8BRRa-nCd5AdpADFLzGyoYlmFTxD_xMSgRO_uc3gCZmdfL76NM3TFQq5BVMMfV3DCs_LiS0sND5vpAXzzEJVCwMCC7LijQ1FFbxXDrSGJJMwHrTSTEKhTPDVU7LX9Z1_RmhwTsDYqgoWMFhp1cQrq4oGIZYwRaMy8mYrUL3YMGXoDScy0yh2HcWekY8o610MZLeOL_rlN50aiwarajiUUHHluBO1coW3gNSMRIzXmIwcbDWlU5Nb6b8VJCOvd8HQWHAFxHS-X8c4vIQRHJZDjTQ8KtA4pGu_R9ptwM7QASqZkXexMtzyl_r0bCai6_ntRX1F7k-vLs71-enllxfkAQPEtDnoeED2huXaHwLiGZqXsVrfAIa0Ad8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRCXFQgQYRcIghNSaOJH7J4Qr2p3gRUSVOrNcvxYgtiktKkQ_54Z1y2Ew0o55OHEjmfs-cYefybkOfe-FF6ygkpXF5w6WZhGTgtRu1pyW0kb0FH8dF6fzPnZQixS_NM6hVXu-sTYUbve4hj5hMVFnQAnqklIYRGf381eLX8WuIMUzrSm7TSukxsSvBTUcLmQ-_EWiuRknO4ZSumk_b4RLysqJR3ZpEjdP8Kb_0dL_otioxma3SaHCT_mr7cCv0Ou-e4uGb78aocYFJnbdr3E8LYuH_rcmlXTp0s4QD6XacHV7xzAan7pB4MrilqbL30H2cEboAQrTGzyRLkKF0P_A16CU_zmLoN7ZD57__XtSZG2UygsmGXo9xpael5NbWmhIXojLZhqGlgtDGcsSMYbG0oWvFcOJIiEk-AbWmmmoVQmeHafHHR95x-QPDgnwM9iwQIeq6yaemVV2SDcEqZsVEae7SpUL7esGXrLj0w1VruO1Z6RN1jX-xTIdB1v9KsLnRqOBgtrOJRQceW4E7VypbeA2oxEvNeYjBzvJKVT81vrv8qSkaf7x9BwcDbEdL7fxDS8Am8Oy6FGEh4VaPyka79FCm7A0dAZKpmRF1EZrvhLfXo2F_Hs4dVFfUJugkbrj6fnH47ILQrgabvm8ZgcDKuNfwTgZ2geR63-A4pGBh0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Switching+cisplatin+to+carboplatin+in+chemotherapy+for+metastatic+penile+cancer+in+a+patient+intolerant+to+cisplatin&rft.jtitle=IJU+case+reports&rft.au=Sekine%2C+Keita&rft.au=Suyama%2C+Takahito&rft.au=Takei%2C+Kazuki&rft.au=Kato%2C+Hiroto&rft.date=2024-11-01&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2577-171X&rft.volume=7&rft.issue=6&rft.spage=434&rft.epage=437&rft_id=info:doi/10.1002%2Fiju5.12772&rft.externalDBID=PMC11531887 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2577-171X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2577-171X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2577-171X&client=summon |